Health Care

Illumina insider trades are routine, compliant, and market‑congruent—no abnormal volatility or price manipulation detected in recent Form 4 & Rule 144 filings.

Explore Kangmei Pharmaceutical’s leadership shift: interim chairman Ou Guoxiong, Guangyao Group’s influence, and the impact on governance, profitability, and investor confidence.

Argenx SE’s rally hinges on Vyvgart’s strong sales and promising myositis trials, yet its single‑drug focus and regulatory hurdles create a high‑risk, high‑reward outlook for investors.

BD’s latest Form 144 is a routine share sale, not a strategic shift, yet the company’s strong revenue, cash flow and investment in point‑of‑care and remote monitoring technologies keep it well‑positioned to drive better clinical outcomes and shareho…

Merck’s Phase‑3 success for a personalized mRNA melanoma vaccine fuels an 8% share jump and signals a new, fast‑tracked oncology therapy.

Explore how Thermo Fisher Scientific’s recent insider trades reveal a strategic liquidity play, boosting investor confidence and navigating biotech’s fast‑moving market.

United Therapeutics execs buy, sell, and plan a Rule 144 sale—insider moves reveal portfolio strategy, market confidence, and potential liquidity impact.

Veeva Systems’ 8‑K filing announces Dan Rizzo as EVP of Sales, Consulting & Services as Thomas Schwenger departs, signaling a strategic shift in leadership and market focus.

Two high‑profile tech debuts hit 1,000 yuan, then fell as AI‑robotics hype cooled—learn how valuation, market sentiment and fundamentals are reshaping STAR Market.

Explore why UBS’s bullish upgrade lifted Sartorius’ stock and how its AI‑driven bioprocess solutions, consumable sales, and M&A plans drive future growth.